MJA
MJA InSight
MJA Careers
Research

Glucose tolerance abnormalities in Australian women with polycystic ovary syndrome

Preeti Dabadghao, Bronwen J Roberts, Jim Wang, Michael J Davies and Robert J Norman
Med J Aust 2007; 187 (6): 328-331.
Abstract

Objectives: To determine the prevalence of glucose tolerance abnormalities and to identify associated risk factors in women with polycystic ovary syndrome (PCOS) attending a reproductive endocrinology clinic.

Design: Retrospective chart review.

Participants and setting: 372 women with confirmed PCOS attending a reproductive endocrinology clinic at Adelaide University’s Research Centre for Reproductive Health.

Main outcome measures: Prevalence of glucose tolerance abnormalities and association of such abnormalities with potential risk factors.

Results: 4.0% (15 women) had diabetes mellitus, 15.6% (58) had impaired glucose tolerance and 80.4% (299) had normal glucose tolerance. There was a significant trend towards increasing prevalence of diabetes with increasing age (odds ratio [OR], 0.60; P = 0.0085). The prevalence of abnormal glucose tolerance (diabetes and impaired glucose tolerance together) was significantly higher with higher waist circumference (OR, 2.9; P = 0.05), higher body mass index (OR, 8.02; P = 0.0253), a family history of diabetes (OR, 1.56; P = 0.0192) and the presence of metabolic syndrome (OR, 5.62; P < 0.001).

Conclusion: The prevalence of diabetes and impaired glucose tolerance is high in women with PCOS, especially in older women and those with abdominal obesity and a family history of diabetes.

Polycystic ovary syndrome (PCOS) is the most frequent endocrine disorder in women.1-4 Its clinical presentation is heterogeneous, and commonly includes menstrual irregularities, infertility, hirsutism, and acne. Metabolic syndrome and its components are more common in women with PCOS compared with age-matched controls.5

Women with PCOS have peripheral insulin resistance independent of body mass index (BMI), fat-free mass and fat distribution, with up to 60% of lean women with PCOS showing fasting hyperinsulinaemia.6-9 Most women with PCOS compensate fully for their insulin resistance, but a substantial proportion, especially those with first-degree relatives with type 2 diabetes, have decreased β-cell response to meals, or rising glucose levels.10,11 Insulin resistance combined with β-cell dysfunction results in an increased prevalence of impaired glucose tolerance (IGT) and type 2 diabetes mellitus (DM) in these women.12,13

Previous studies in the United States have shown that women with PCOS have a higher prevalence of diabetes (8%–12%) and impaired glucose tolerance (30%–35%) than normal women of the same age.12,13 In contrast, the prevalence of diabetes is lower in Mediterranean regions, with an Italian study reporting prevalences of 15.5% for impaired glucose tolerance and 2.5% for diabetes in women with PCOS.14 In a Dutch follow-up study in a relatively lean population of women with PCOS, the prevalence of diabetes was increased compared with the general female population, especially in women aged 45–54 years.15

There is a paucity of published data on the prevalence of glucose intolerance in women with PCOS in Australia. Here, we report a retrospective data analysis on a large cohort of women with PCOS attending a reproductive endocrinology clinic at our centre. Our aims were to determine the prevalence of glucose tolerance abnormalities and to identify associated risk factors.

Methods

Case records of 660 women presumed to have PCOS because of a history of chronic anovulation or infertility or oligomenorrhoea or features of hyperandrogenism were reviewed. These women were attending reproductive endocrine clinics for treatment of infertility or features of PCOS. PCOS was confirmed in 372 women based on the presence of two of the following three features:

  • chronic anovulation, oligomenorrhoea or menstrual irregularities;

  • clinical or biochemical evidence of hyperandrogenism; and

  • presence of polycystic ovaries on ultrasound in the absence of other disorders such as hypothyroidism, Cushing’s syndrome, hyperprolactinaemia or ovarian and adrenal causes of hyperandrogenism.

These features are known as the Rotterdam 2003 criteria.16 Inclusion criteria were a previously normal result on an oral glucose tolerance test (OGTT), being contactable by phone and willingness to participate. Exclusion criteria were no previous OGTT and unwillingness to participate.

Information about: age; menarche; menstrual cycles; presence or absence of hirsutism; acne; family history of diabetes and PCOS; anthropometric measurements of weight, height, waist circumference and blood pressure; blood levels of various hormones; and OGTT results with insulin and lipid profile were collected from case notes. Normal glucose tolerance (NGT), DM and IGT were defined according to the criteria proposed by the World Health Organization.17 Impaired fasting glycaemia (IFG) was defined by the recommendations of the expert committee of the American Diabetes Association.18 The presence of metabolic syndrome was defined according to guidelines of the Third Report of the National Cholesterol Education Program Expert Panel.19 A family history of diabetes was considered positive if any first-degree relative (parent or sibling) had a history of DM. Body mass index (BMI) was calculated by the formula: weight in kilograms/(height in metres)2. A BMI of 18–25 was considered normal, 25.01–30 overweight and > 30.01 obese. Measures of insulin resistance were derived through homeostatic model assessment for insulin resistance (HOMA-IR) and the Quantitative Insulin Sensitivity Check Index 1 (QUICKI1).20

Glucose was measured by the glucose oxidase method, and other hormone levels were measured by previously described methods.21 Testosterone was measured by radioimmunoassay (RIA) kits (Farmos Diagnostica, Turku, Finland). Insulin was measured by RIA kits from Pharmacia (Sydney, NSW, Australia), and had a cross-reactivity with proinsulin of about 20%. Intra-assay and inter-assay coefficients of variation were 7% and 10%, respectively, for both testosterone and insulin.

Ethical approval was received from the Human Research Ethics Committee of the Women’s and Children’s Hospital, Adelaide.

Statistical analysis

All data are expressed as mean ± SD and frequencies (%). Categorical data were analysed with the χ2 test, while analysis of variance or Student’s t test were used to analyse the difference between groups in continuous variables. A two-tailed P value of < 0.05 was considered statistically significant. SPSS software, version 13 (SPSS Inc, Chicago, Ill, USA) was used for statistical analysis.

Results

The mean age of the 372 women with PCOS was 30.3 ± 5.6 years (median, 30.4 years; range; 15–62 years), and their mean BMI was 35.1 ± 8.0 kg/m2. With the exception of one woman, all of the 73 women with either diabetes or IGT were overweight or obese compared with 84% of the 299 women with NGT. Forty-four per cent of all 372 women had a family history of diabetes. The prevalences of oligomenorrhoea, hirsutism and acne were 75%, 65% and 40%, respectively.

According to WHO criteria based on a 2-hour postload glucose measurement during an OGTT,17 of the 372 women with PCOS, 4.0% (15) had DM, 15.6% (58) had IGT, and 80.4% (299) had NGT. When fasting glucose levels were analysed according to the recommendations of the American Diabetes Association,18 2.7% (10) had DM, 3.0% (11) had IFG and 94.6% (352) had normal fasting glucose levels. The clinical and biochemical features of the women grouped according to their OGTT results are summarised in Box 1.

Women who had diabetes were significantly older (P = 0.003) than those who had IGT or normal glucose tolerance (Box 1). There was no difference between the three groups in weight and BMI, but women with diabetes or IGT had predominantly abdominal obesity and a significantly higher waist circumference (P = 0.001) than those in the NGT group. There was no difference between groups with respect to age of menarche, frequency of menstrual irregularities, acne and hirsutism.

As expected, the DM and IGT groups had significantly higher fasting insulin levels than the NGT group (P < 0.0001). Women with diabetes and IGT had marked insulin resistance as shown by the higher HOMA-IR (P < 0.0001) and lower QUICKI1 (P < 0.0001) values compared with the NGT group (Box 1). In the NGT group, obese patients had significantly higher fasting and 2-hour glucose levels (P < 0.001), and they were insulin resistant compared with normal-weight patients. Lipid profiles were comparable in the three groups.

Box 2 shows the prevalence of glucose tolerance abnormalities by age range for the three groups. There was a significant trend of an increasing prevalence of DM with increasing age (P = 0.0085).

Box 3 examines the prevalence of abnormal glucose tolerance in relation to age, BMI, waist circumference, family history of diabetes and metabolic syndrome. The prevalence of abnormal glucose tolerance (DM and IGT together) was higher with higher waist circumference (P = 0.05) and increased BMI (P = 0.0253). A higher prevalence of DM was seen in women with a family history of diabetes (P = 0.0192) and in those with metabolic syndrome (P < 0.001). When multiple logistic regression was applied using all these factors, only the presence of metabolic syndrome was independently associated with an increase in glucose tolerance abnormality (odds ratio, 2.213; 95% CI, 1.061–4.617).

Discussion

To our knowledge, this is the first study to describe the range of glucose abnormalities in an Australian population of women with PCOS defined by the Rotterdam criteria. The prevalence of DM in our study was 4.0% and that of IGT was 15.6%, both of which are higher than the prevalences of these conditions in the general population of Australian women of similar age.22 We have previously reported a high rate of conversion to glucose intolerance or DM in a similar cohort.23 The high prevalences of IGT and DM in this population are probably the consequence of insulin resistance coupled with obesity. These prevalences are comparable to those reported in Italian women with PCOS, but are lower than those reported in women with PCOS in the US and Asia.12-14,24 This discrepancy could be the result of differences in the study populations or in the diagnostic criteria used to define PCOS; another possible reason for the discrepancy with the US study is the prevalence of obesity, which is much higher in the American population. It has been shown that women with PCOS from South Asia have higher fasting insulin concentrations and lower insulin sensitivity than white women.25 Much harder to define and probably equally influential are the effects of genetic, environmental and lifestyle factors on the manifestation of the clinical features, including insulin levels, in women with PCOS.14

The above findings were based on 2-hour postload OGTT results. If we base them on fasting glucose levels, as recommended by the American Diabetes Association, five women diagnosed to have diabetes by OGTT would have been missed. Similarly, in an Australian study based on fasting glucose levels, diabetes was diagnosed in 1.8% of participants.26 This is substantially lower than the rate of 2.9% based on 2-hour postload glucose criteria alone, and than the rate of 3.7% based on both the values, as recommended by the WHO.26 Thus, 2-hour postload OGTT may be required in populations at higher risk of diabetes, like women with PCOS or certain ethnic groups.

Women with PCOS with obesity and glucose intolerance are characteristically more insulin resistant and have more hyperandrogenism. It has been reported that there is a higher frequency of oligomenorrhoea or hirsutism in women with IGT.14 However, we found that frequencies of oligomenorrhoea, hirsutism and acne and mean androgen levels were comparable in all groups irrespective of OGTT results, and were higher than those reported from Italy. This probably reflects a high proportion of infertile patients in our study group.

We also identified demographic risk factors for developing DM or IGT in our cohort. Women with DM were significantly older than those with IGT and NGT, similar to earlier reports.12,14 The significant trend of increasing prevalence of DM with increasing age concurs with the findings of previous studies.27 Obesity, particularly abdominal obesity, increases the risk of DM. Women with DM and IGT had a significantly higher waist circumference than women in the NGT group. The prevalence of abnormal glucose tolerance (DM and IGT together) was significantly higher among women with a waist circumference over 88 cm. A family history of diabetes is an important risk factor for glucose tolerance abnormalities, and the prevalence of DM was significantly higher in such women in our cohort. It has previously been reported that women with PCOS and DM had a 2.6-fold higher prevalence of a family history of DM.12 Insulin resistance and hyperinsulinaemia not only increase the risk of DM, but are also correlated with an increased risk of cardiovascular disease and are a main pathogenic mechanism of metabolic syndrome. The prevalence of DM was significantly higher in women who had features of metabolic syndrome.

The strengths of our study include its having the largest cohort of women with PCOS reported worldwide, that the diagnosis of PCOS was based on the newly established Rotterdam 2003 criteria,16 and that OGTT was prospectively carried out. Its major limitations are its retrospective data collection (resulting in some missing measurements), and that patients were recruited from an infertility clinic, so there could be a selective bias to a particular type of PCOS.

To conclude, our study shows that the prevalence of glucose intolerance abnormalities is high in women with PCOS, especially in older women and those with abdominal obesity and a family history of diabetes. It is recommended that all women with PCOS have a 2-hour postload OGTT and lipid profile testing at diagnosis. Regular follow-up can be useful in both long-term clinical management and encouraging patient lifestyle modification.

1 Clinical and biochemical parameters of 372 women with polycystic ovary syndrome

Parameter

Diabetes mellitus

Impaired glucose tolerance

Normal glucose tolerance

P*


No. of women

15

58

299

Age (years)

35.7 ± 6.5

30.7 ± 4.8

29.9 ± 5.5

0.003

Family history of diabetes

62% (8/13)

28% (16/47)

0.014

Weight (kg)

103.1 ± 23.7

101.8 ± 21.6

92.0 ± 20.6

0.051

BMI (kg/m2)

38.3 ± 8.2

37.9 ± 7.5

35.14 ± 7.60

0.047

Waist (cm)

122.8 ± 10.5

109.1 ± 16.5

98.9 ± 15.3

0.001

Testosterone (nmol/L)

3.0 ± 1.7

3.6 ± 2.5

3.2 ± 2.8

ns

Sex hormone binding globulin (nmol/L)

16.1 ± 15.2

19.7 ± 18.7

27.6 ± 28.9

ns

Fasting insulin (mIU/L)

33.2 ± 15.8

22.3 ± 11.4

15.8 ± 12.2

0.001

2-hour postload insulin (mIU/L)

132.2 ± 89.5

171.9 ± 85.7

80.1 ± 60.7

0.001

Fasting glucose to insulin ratio

0.36 ± 0.26

0.37 ± 0.29

0.44 ± 0.26

0.001

HOMA-IR (ratio)

12.3 ± 4.1

5.2 ± 2.9

3.4 ± 2.9

0.001

QUICKI1 (ratio)

0.41 ± 0.02

0.52 ± 0.17

0.58 ± 0.10

0.001


* One-way analysis of variance. Values are mean ± SD. Measure of insulin resistance. BMI = body mass index. ns = not significant. HOMA-IR = homeostatic model assessment for insulin resistance. QUICKI1 = Quantitative Insulin Sensitivity Check Index 1.

2 Prevalence of glucose intolerance by age of women with polycystic ovary syndrome

Age (years)

Total number

Diabetes mellitus

Impaired glucose tolerance

Normal glucose tolerance


14–20

16

0

6.3% (1)

93.8% (15)

> 20–25

45

2.2% (1)

11.1% (5)

86.7% (39)

> 25–30

118

1.7% (2)

15.3% (18)

83.1% (98)

> 30–35

127

3.9% (5)

19.7% (25)

76.4% (97)

> 35–40

48

4.2% (2)

16.7% (8)

79.2% (38)

> 40–45

12

25.0% (3)

8.3% (1)

66.7% (8)

> 45–50

2

50.0% (1)

0

50.0% (1)

> 50

1

0

0

100% (1)

3 Prevalence of abnormal oral glucose tolerance test outcome by potential demographic risk factors in women with polycystic ovary syndrome

Variables

Total number

Abnormal
glucose tolerance*

Normal
glucose tolerance

OR (95% CI)


Age (years)

< 30

181

28

153

0.60 (0.35–1.03)

≥ 30

188

44

144

Waist (cm)

> 88

195

40

155

2.90 (0.99–8.56)

≤ 88

49

4

45

BMI (kg/m2)

< 25

36

2

34

8.02 (1.87–34.38)

≥ 25

219

67

142

Family history of diabetes

Yes

91

24

67

1.56 (0.86–2.80)

No

192

36

156

Metabolic syndrome

Yes

100

36

64

5.62 (2.73–11.56)

No

132

12

120


* Diabetes mellitus and impaired glucose tolerance groups. OR = odds ratio. BMI = body mass index.

Received 
16 Nov 2006
accepted 
25 Apr 2007
Preeti Dabadghao, MD, Visiting Fellow
Bronwen J Roberts, RN, Nurse
Jim Wang, PhD, Research Fellow
Michael J Davies, BA(Hons), MPH, PhD, Fellow
Robert J Norman, MD, FRACOG, CREI, Director
Research Centre for Reproductive Health, Discipline of Obstetrics and Gynaecology, University of Adelaide, Adelaide, SA.
Competing Interests: 

None identified.

Reference Text: 
Asuncion M, Calvo RM, San Millan JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 2434-2438.
Reference Order: 
1
PubMed ID: 
10902790
Reference Text: 
Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999; 84: 4006-4011.
Reference Order: 
2
PubMed ID: 
10566641
Reference Text: 
Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853-861.
Reference Order: 
3
PubMed ID: 
7651477
Reference Text: 
Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078-3082.
Reference Order: 
4
PubMed ID: 
9745406
Reference Text: 
Glueck CJ, Papanna R, Wang P, et al. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003; 52: 908-915.
Reference Order: 
5
PubMed ID: 
12870169
Reference Text: 
Ciaraldi TP, el-Roeiy A, Madar Z, et al. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 1992; 75: 577-583.
Reference Order: 
6
PubMed ID: 
1322430
Reference Text: 
Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab 2001; 281: E392-399.
Reference Order: 
7
PubMed ID: 
11440917
Reference Text: 
Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.
Reference Order: 
8
PubMed ID: 
9408743
Reference Text: 
Book CB, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1999; 84: 3110-3116.
Reference Order: 
9
PubMed ID: 
10487672
Reference Text: 
O’Meara NM, Blackman JD, Ehrmann DA, et al. Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993; 76: 1241-1247.
Reference Order: 
10
PubMed ID: 
8496316
Reference Text: 
Ehrmann DA, Breda E, Corcoran MC, et al. Impaired beta-cell compensation to dexamethasone-induced hyperglycemia in women with polycystic ovary syndrome. Am J Physiol Endocrinol Metab 2004; 287: E241-246.
Reference Order: 
11
PubMed ID: 
14665448
Reference Text: 
Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22: 141-146.
Reference Order: 
12
PubMed ID: 
10333916
Reference Text: 
Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84: 165-169.
Reference Order: 
13
PubMed ID: 
9920077
Reference Text: 
Gambineri A, Pelusi C, Manicardi E, et al. Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes 2004; 53: 2353-2358.
Reference Order: 
14
PubMed ID: 
15331545
Reference Text: 
Elting MW, Korsen TJ, Bezemer PD, Schoemaker J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 2001; 16: 556-560.
Reference Order: 
15
PubMed ID: 
11228228
Reference Text: 
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
Reference Order: 
16
PubMed ID: 
Reference Text: 
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
Reference Order: 
17
PubMed ID: 
9686693
Reference Text: 
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
Reference Order: 
18
PubMed ID: 
9203460
Reference Text: 
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
Reference Order: 
19
PubMed ID: 
11368702
Reference Text: 
Katsuki A, Sumida Y, Gabazza EC. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 2001; 24: 362-365.
Reference Order: 
20
PubMed ID: 
11213893
Reference Text: 
Norman RJ, Masters SC, Hague W, et al. Metabolic approaches to the subclassification of polycystic ovary syndrome. Fertil Steril 1995; 63: 329-335.
Reference Order: 
21
PubMed ID: 
7843439
Reference Text: 
Dunstan DW, Zimmet PZ, Welborn TA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002; 25: 829-834.
Reference Order: 
22
PubMed ID: 
11978676
Reference Text: 
Norman RJ, Masters L, Milner CR, et al. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001; 16: 1995-1998.
Reference Order: 
23
PubMed ID: 
11527911
Reference Text: 
Weerakiet S, Srisombut C, Bunnag P, et al. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. Int J Gynaecol Obstet 2001; 75: 177-184.
Reference Order: 
24
PubMed ID: 
11684113
Reference Text: 
Wijeyaratne CN, Balen AH, Barth JH, Belchetz PE. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol (Oxf) 2002; 57: 343-350.
Reference Order: 
25
PubMed ID: 
12201826
Reference Text: 
Colagiuri S, Cameron A, Hussain Z, et al. Screening for type 2 diabetes and impaired glucose metabolism. The Australian experience. Diabetes Care 2004; 27: 367-371.
Reference Order: 
26
PubMed ID: 
14747215
Reference Text: 
Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 1998; 21: 518-524.
Reference Order: 
27
PubMed ID: 
9571335